Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 3, 2012, Pages 233-240

  Zhao, Ming ^a   He, Xi ^a   Zhao, Mei ^a   Bi, Xue Yuan ^a   Zhang, Hong Li ^a   Yu, Xiao Jiang ^a   Liu, Jin Jun ^a   Li, Dong Ling ^a   Ma, Xin ^a   Zang, Wei Jin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Celecoxib; Coronary vessels; Myocardial ischaemia; Nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CREATINE KINASE; CYCLOOXYGENASE 2; MALONALDEHYDE; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; MUSCLE ISOMETRIC CONTRACTION; MYOGRAPHY; NONHUMAN; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION;

ACUTE DISEASE; ANIMALS; CORONARY VESSELS; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MYOCARDIAL ISCHEMIA; PYRAZOLES; RABBITS; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84863131383     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05664.x     Document Type: Article

References (40)

1. Vane RJ, Bakhle SY, Botting MR. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 97-120.
2. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol. Pharmacol. 2009; 76: 1053-61.
3. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
4. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch. Intern. Med. 2005; 165: 161-8.
5. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44.
6. White WB, West CR, Borer JS et al. Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. Am. J. Cardiol. 2007; 99: 91-8.
7. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults. Ann. Intern. Med. 2005; 142: 481-9.
8. Gudbjornsson B, Thorsteinsson SB, Sigvaldason H et al. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. Eur. J. Clin. Pharmacol. 2010; 66: 619-25.
9. Hermann M, Camici G, Fratton A et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308-11.
10. Chenevard R, Hürlimann D, Béchir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-9.
11. Sun L, Lu J, Yu XJ et al. Adenine sulfate improves cardiac function and the cardiac cholinergic system after myocardial infarction in rats. J. Pharmacol. Sci. 2011; 115: 205-13.
12. López-Farré A, Riesco A, Digiuni E et al. Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischaemia in rabbits. Circulation 1996; 94: 83-7.
13. Tan J, Ma Z, Han L et al. Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: H2265-71.
14. Tissier R, Souktani R, Bruneval P, Giudicelli JF, Berdeaux A, Ghaleh B. Adenosine A(1)-receptor induced late preconditioning and myocardial infarction: Reperfusion duration is critical. Am. J. Physiol. Heart Circ. Physiol. 2002; 283: H38-43.
15. Yan J, Qian Z, Sheng L et al. Effect of crocetin on blood pressure restoration and synthesis of inflammatory mediators in heart after hemorrhagic shock in anesthetized rats. Shock 2010; 33: 83-7.
16. He X, Zhang HL, Zhao M et al. Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2011; 38: 255-61.
17. Xi S, Yin W, Wang Z et al. A minipig model of high-fat/high-sucrose diet-induced diabetes and atherosclerosis. Int. J. Exp. Pathol. 2004; 85: 223-31.
18. 2+ entry in adenosine-induced vasodilatation of rat small mesenteric artery. Am. J. Physiol. Heart Circ. Physiol. 2009; 297: H347-54.
19. Wang Y, Wang S, Wier WG et al. Exercise improves the dilatation function of mesenteric arteries in postmyocardial infarction rats via a PI3K/Akt/eNOS pathway-mediated mechanism. Am. J. Physiol. Heart Circ. Physiol. 2010; 299: H2097-106.
20. Luo HL, Zang WJ, Lu J, Yu XJ, Lin YX, Cao YX. The protective effect of captopril on nicotine-induced endothelial dysfunction in rat. Basic Clin. Pharmacol. Toxicol. 2006; 99: 237-45.
21. Wilner KD, Rushing M, Walden C et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J. Clin. Pharmacol. 2002; 42: 1027-30.
22. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am. J. Cardiol. 2008; 101: 1060-3.
23. Rimon G, Sidhu RS, Lauver DA et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc. Natl Acad. Sci. USA 2010; 107: 28-33.
24. Bonow RO, Lipson LC, Sheehan FH et al. Lack of effect of aspirin on myocardial infarct size in the dog. Am. J. Cardiol. 1981; 47: 258-64.
25. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of COX pathway in experimental myocardial infarction. J. Mol. Cell. Cardiol. 2004; 37: 71-7.
26. Lada-Moldovan L, Kaloustian S, Bah TM, Girard SA, Déry MA, Rousseau G. Chronic pretreatment with celecoxib reduces infarct size. J. Cardiovasc. Pharmacol. 2009; 54: 31-7.
27. Malek HA, Saleh DM. Cyclooxygenase-2 inhibitor celecoxib in a rat model of hindlimb ischemia reperfusion. Can. J. Physiol. Pharmacol. 2009; 87: 353-9.
28. Ozturk H, Gezici A, Ozturk H. The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol. Res. 2006; 34: 76-83.
29. Romero FI, Martínez-Calatrava MJ, Sanchez-Pernaute O, Gualillo O, Largo R, Herrero-Beaumont G. Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. Br. J. Pharmacol. 2010; 161: 1012-22.
30. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. J. R. Soc. Med. 2006; 99: 132-40.
31. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the riak of atherothrombosis? Meta-analysis of randomised trials BMJ 2006; 332: 1302-5.
32. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008; 22: 659-61.
33. Shinmura K, Xuan YT, Tang XL et al. Inducible nitric oxide synthase modulates cyclo-oxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ. Res. 2002; 90: 602-8.
34. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor κB in myocardium of patients with congestive heart failure. Circulation 1998; 98: 100-3.
35. Abbate A, Santini D, Biondi-Zoccai GG et al. Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: Friend or foe? Heart 2004; 90: 440-3.
36. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H1416-24.
37. Rossoni G, Muscara MN, Cirino G, Wallace JL. Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br. J. Pharmacol. 2002; 135: 1540-6.
38. Shinmura K, Tang XL, Wang Y et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl Acad. Sci. USA 2000; 97: 10197-202.
39. Abbate A, Limana F, Capogrossi MC et al. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. Apoptosis 2006; 11: 1061-3.
40. Klein T, Eltze M, Grebe T, Hatzelmann A, Kömhoff M. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc. Res. 2007; 75: 390-7.